title: [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
abstract: We performed a retrospective long-term study to evaluate the efficacy of intravesical instillation of Tokyo 172 strain Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder. Between 1989 and 1998, 42 patients with CIS of bladder underwent intravesical instillation of BCG. In the follow-up period from 6 to 116 months (mean: 37.3 months), the efficacy rate of intravesical BCG instillation for CIS of the bladder was 81.0%. Two patients died from the bladder cancer. The non-recurrence rate in patients with grade 2 carcinoma (19 cases) was not significantly different from that in those with grade 3 carcinoma (23 cases). However, the recurrence rate in patients with secondary CIS (15 cases) was significantly higher than in those with primary CIS (27 cases). The recurrence of CIS was observed in 7 of 42 cases. In 6 of 7 patients, CIS recurred within one year after treatment. Total cystectomy was performed in 10 of 42 patients, and pathological findings of muscle layer invasion were detected in 8 patients. Although side effects occurred in 33 patients (77.5%), no clinically significant side effects were observed. Our results suggest that intravesical BCG therapy may be useful for the treatment of CIS of the bladder.
authors.affiliation: Dept. of Urology, Gifu University School of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Nishino
authors.forename: M
authors.initials: M
authors.lastname: Yasuda
authors.forename: S
authors.initials: S
authors.lastname: Yokoi
authors.forename: H
authors.initials: H
authors.lastname: Ehara
authors.forename: N
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Ishihara
authors.forename: T
authors.initials: T
authors.lastname: Deguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kawada
authors.forename: A
authors.initials: A
authors.lastname: Takeda
authors.forename: S
authors.initials: S
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
authors.forename: M
authors.initials: M
authors.lastname: Taniguchi
authors.forename: K
authors.initials: K
authors.lastname: Minoshima
authors.forename: Y
authors.initials: Y
authors.lastname: Hamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kanimoto
authors.forename: M
authors.initials: M
authors.lastname: Nakano
authors.forename: S
authors.initials: S
authors.lastname: Fujihiro
authors.forename: S
authors.initials: S
authors.lastname: Nezasa
authors.forename: T
authors.initials: T
authors.lastname: Matsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Nagatani
authors.forename: S
authors.initials: S
authors.lastname: Maeda
authors.forename: M
authors.initials: M
authors.lastname: Tamaki
authors.forename: A
authors.initials: A
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Komeda
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine